ReviewFrontiers in endocrinology2021
The Stability of TSH, and Thyroid Hormones, in Patients Treated With Tablet, or Liquid Levo-Thyroxine.
Review in Frontiers in endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- Editorial: Levothyroxine therapy in patients with hypothyroidism, volume II.Frontiers in endocrinology · 2026Article
- Treatment of hypothyroidism with the combination of levothyroxine and slow-release triiodothyronine: a randomized clinical trial.Journal of clinical & translational endocrinology · 2025Article
- Are liquid levothyroxine formulations comparable? The LETI study.Thyroid research · 2025Article
- Thyroid hormone use in clinical practice by Israeli endocrinologists: a THESIS* questionnaire survey : *Treatment of hypothyroidism in Europe by specialists: an international survey.Thyroid research · 2025Article
- Levothyroxine therapy in thyroidectomized patients: ongoing challenges and controversies.Frontiers in endocrinology · 2025Review
- Beyond the Thyroid: A Narrative Review of Extra-thyroidal Manifestations in Hashimoto's Disease.Cureus · 2024Review
- Liquid L-T4 therapy in hypothyroid patients with gastric diseases, an observational study.Frontiers in endocrinology · 2024Observational
- Hypothyroidism and metabolic cardiovascular disease.Frontiers in endocrinology · 2024Review
- Myxedema coma secondary to levothyroxine malabsorption in a patient previously submitted to bariatric surgery.Archives of endocrinology and metabolism · 2024Article
- Lactose intolerance and levothyroxine malabsorption: a review of the literature and report of a series of patients treated with liquid L-T4 without lactose.Frontiers in endocrinology · 2024Review
- Levothyroxine personalized treatment: is it still a dream?Frontiers in endocrinology · 2023Article
- Management of Hypothyroidism in Internal Medicine: Patient Profile and Effects of an Educational Programme in the Cluster-Randomized FADOI TIAMO Study.Frontiers in endocrinology · 2022Article
- Effectiveness and Safety of Levothyroxine Tablets Combined with Iodine-131 in the Treatment of Thyroid Cancer.Journal of oncology · 2022Article
- Comparison Among Two Liquid Formulations of L-thyroxine in the Treatment of Congenital Hypothyroidism in the First Month of Life: A Pilot Study.Frontiers in endocrinology · 2022Article
- Congenital Hypothyroidism in Preterm Newborns - The Challenges of Diagnostics and Treatment: A Review.Frontiers in endocrinology · 2022Review
- Liquid levothyroxine formulations in patients taking drugs interfering with L-T4 absorption.Frontiers in endocrinology · 2022Review
- Precision Medicine in Autoimmune Thyroiditis and Hypothyroidism.Frontiers in pharmacology · 2021Review
- Daily Intramuscular Levothyroxine in Refractory Hypothyroidism and Malabsorption.AACE endocrinology and diabetesArticle
- Role of T3 in Management of Hypothyroidism.Indian journal of endocrinology and metabolismReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Approximately, 5% of the population is affected by hypothyroidism, mainly women and persons aged more than 60 years. After the diagnosis of hypothyroidism the usual therapy is tablet levothyroxine (L-T4), with a monitoring of the thyroid-stimulating hormone (TSH) level in primary hypothyroidism every 6-8 weeks and L-T4 is adjusted as necessary to reach an euthyroid state. Once TSH is stabilized in the normal range, it is recommended to conduct annual testing in the treated subjects to warrant suitable replacement. More recently advances regarding L-T4 treatment are the introduction of new oral formulations: the liquid solution, and soft gel capsule. The soft gel capsule permits a quick dissolution in the acid gastric pH. The liquid preparation does not require an acid gastric environment. Many pharmacokinetic studies demonstrated a more rapid absorption for the liquid L-T4, or capsule, than with tablet. Many studies have shown that the liquid, or capsule, formulations can overcome the interaction with foods, drugs or malabsorptive conditions, that are able to impair the tablet L-T4 absorption. Lately studies have suggested that liquid L-T4 can permit to maintain more efficiently normal TSH levels in hypothyroid patients in the long-term follow-up, than tablet L-T4, both in patients with malabsorptive states, and in those without malabsorption. Further large, prospective, longitudinal studies are needed to evaluate the stability of TSH, in hypothyroid patients treated with different L-T4 formulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.